In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best humane stocks to invest in now. In recent years, the investment landscape has ...

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $105.00. Mohit Bansal has given his Buy ...

$2,440,000 of GILEAD SCIENCES INC lobbying was just disclosed ... testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price target of $84.00. The company’s shares ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients.

**NM signifies a non meaningful value. A dash signifies the data is not available.

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers ...

A high-tech mobile screening unit helping to save lives through earlier diagnosis of lung cancer hit on potential problems during a recent cold snap. The NHS Targeted Lung Health Check Service had ...